KMT2A and acute myeloid leukemia: AML patients bearing MLL translocations have an intermediate-to-poor prognosis (5-year disease-free survival of 30%-60%), and their leukemia cells are often resistant to conventional chemotherapies. It was shown that PARP1 contributes to the maintenance of MLL-AF9 leukemias.